The 2026 Global Delphi Consensus on Acne and the Microbiome supports microbiome-targeted care for acne and gives acne-prone shoppers a way to test product claims. A Delphi consensus is a structured vote by independent experts, and here the panel backed prebiotics, probiotics and postbiotics as part of acne therapy. The skin microbiome means the bacteria, fungi and other microbes living on skin. For acne-prone readers, the practical question is whether a cleanser, serum or supplement has direct proof for its finished formula.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the experts decide?
- Why does bacterial balance matter more than amount?
- Where are the limits for buyers?
- How should you read microbiome claims on labels?
What did the experts decide?
The paper titled "A Global Delphi Consensus on Acne and the Microbiome" was published in Pharmaceuticals in 2026 as volume 19, article 697, as reported by MDPI/Pharmaceuticals in the journal record. It gathered international expertise on prevention and therapy.
The panel voted 100% in the first electronic round for adopting microbiome-targeted treatments for acne management. It also reached 89% agreement that the microbiome affects acne severity, the gut-skin axis affects acne, probiotics may help, and prebiotics, probiotics and postbiotics belong in therapy.
Why does bacterial balance matter more than amount?
Acne now links less to total Cutibacterium acnes load than to lost diversity among its strains. A Scientific Reports review describes predominance of type IA1/SLST A1 strains in acne versus protective IB types.
That shift matters for shoppers. A harsh antibacterial wash can reduce total bacteria while leaving an unbalanced strain mix. A microbiome-preserving or rebalancing approach aims to support diversity rather than sterilize skin.
Where are the limits for buyers?
Acne affects about 85% of teenagers plus many adults, according to American Academy of Dermatology reporting, so interest in gentle cleansers and adjuncts is high. Broad demand has brought many "microbiome-friendly" labels to shelves.
Medscape Medical News commentary notes an important limit: biotic therapy is not mentioned in the latest American Academy of Dermatology acne guidelines. The same commentary warns that supplement trials may overstate benefit because companies typically publish only positive studies.
How should you read microbiome claims on labels?
Under FDA policy, a cosmetic that claims to mitigate acne or rosacea is classified as a drug requiring FDA review, while cosmetics may claim only cleansing, beautifying or appearance change, as reported by FDA via Healio in the FDA consumer warning. Strong disease language on a cosmetic jar is therefore a red flag. Ask for proof on the exact product, because FTC law requires competent and reliable evidence for the specific claim, not borrowed general science, as explained in FTC litigation analysis in the probiotic-claims evidence guide.
- Ask whether a randomized trial tested the finished product, not just an ingredient.
- Ask who was studied, for how long, and what changed in lesions, redness or oil.
- Ask whether the result is published and independent of the seller.
- Keep prescription care as the base and treat biotic products as add-ons unless your clinician advises otherwise.
You Might Also Like
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: Product-Claim Questions for People With Acne-Prone Skin
- Why the 2026 Probiotic and Secretome Paper Reports No Trial Results Yet: Evidence Limits and Open Questions for People With Acne-Prone Skin
- What 105 Studies Reveal About Acne AI in the 2026 Review: Accuracy and Validation Questions for People Using Acne Apps